CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 34 enrolled
Drug / intervention
Diacerein 1% ointmentdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03473184
NCT03473184Phase 1Completed

A 4 Day, Randomized Study to Evaluate the Potential of CCP-020 (Diacerein 1%) Topical Ointment to Induce a Phototoxicity Skin Reaction in Healthy Subjects, Using a Controlled Photopatch Test

Castle Creek Pharmaceuticals, LLC·interventional·Posted Mar 22, 2018·Updated Feb 10, 2020

In Brief

A Phase 1 clinical trial evaluating Diacerein 1% ointment for Healthy. Completed, enrolled 34 participants across 1 site.

Detailed Summary

This study was designed to assess the phototoxic potential of diacerein 1% ointment when application is followed by light exposure.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedMar 22, 2018
Enrollment StartDec 12, 2017
Primary CompletionDec 15, 2017
TodayJul 2, 2026
Enrollment to primary: 3 daysPosted 8.3 years ago

Interventions

Diacerein 1% ointmentdrug

Diacerein 1% ointment and vehicle ointment were applied on Day 1 at two randomly assigned skin sites on each side of the lower thoracic area of the back according to a randomization scheme. One side of the back was irradiated on Day 2, including an untreated irradiated control site, and the other side was to remain non-irradiated.